TABLE 1.
Protease inhibitor | EC50 (nM) (fold change compared to HIV-1)
|
|||
---|---|---|---|---|
HIV-1NL4-3 | HIV-2MS | HIV-2CBL-23 | HIV-2CDC310319 | |
APV | 72 ± 30 | 900 ± 63 (12.5) | 939 ± 166 (13.0) | 674 ± 79 (9.2) |
ATV | 5 ± 2 | 20 ± 1 (4.0) | 39 ± 12 (7.8) | 110 ± 34 (22.0) |
DRV | 12 ± 5 | ND | 83 ± 31 (6.9) | 155 ± 52 (12.9) |
IDV | 38 ± 8 | 22 ± 8 (0.5) | 33 ± 8 (0.8) | 108 ± 6 (2.6) |
LPV | 18 ± 3 | 15 ± 7 (0.8) | 12 ± 4 (0.7) | 180 ± 71 (10.0) |
NFV | 18 ± 12 | 48 ± 23 (2.7) | 83 ± 17 (4.6) | 389 ± 66 (21.6) |
RTV | 46 ± 15 | 349 ± 165 (7.6) | 514 ± 172 (11.2) | 665 ± 98 (14.5) |
SQV | 12 ± 1 | 5 ± 1 (0.4) | 8 ± 2 (0.7) | 68 ± 24 (5.7) |
Each EC50 value represents the mean of at least three determinations. ND, not determined.